Exelixis, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
EXEL Nasdaq 2836 www.exelixis.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Exelixis, Inc.

Exelixis, Inc. (EXEL): Renaissance Technologies Likes This Stock - May 30th, 2026 9:54 am
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026 - May 30th, 2026 8:00 am
How The Exelixis (EXEL) Story Is Shifting As Wall Street Reworks Fair Value Targets - May 29th, 2026 7:11 am
Dow Jones Futures Rise As Dell, NetApp Surge On Earnings; Oil Falls On U.S.-Iran Deal Hopes - May 29th, 2026 6:08 am
How Investors Are Reacting To Exelixis (EXEL) Expanding Beyond CABOMETYX With New Colorectal Cancer Trials - May 28th, 2026 11:03 pm
If Decades of History Tell Us Anything, This Biotech Near $50 Is Primed to Skyrocket - May 28th, 2026 8:23 am
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June - May 27th, 2026 2:05 pm
Exelixis Eyes CABO Growth as Zanzalintinib Readouts and Potential CRC Launch Near - May 23rd, 2026 3:04 am
Exelixis (EXEL): 12 Best Low Priced Growth Stocks to Invest In Now - May 22nd, 2026 1:28 pm
Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types - May 21st, 2026 3:00 pm
Assessing Exelixis (EXEL) Valuation After Merck Zanzalintinib Keytruda Colorectal Cancer Collaboration - May 21st, 2026 10:15 am
GlobeFlex Exits NCR Atleos After Brink’s Buyout Deal - May 20th, 2026 3:54 pm
EXEL Collaborates With MRK for Late-Stage Colorectal Cancer Study - May 20th, 2026 12:35 pm
Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer - May 19th, 2026 6:00 am
Prediction: This Stock Could Double By 2031 - May 15th, 2026 5:50 pm
TD Cowen Sees Pipeline Growth Opportunities Supporting Exelixis, Inc. (EXEL) Outlook - May 11th, 2026 2:01 pm
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May - May 7th, 2026 2:05 pm
Why Exelixis (EXEL) Is Up 9.0% After Strong Q1 2026 Earnings And New Buyback Program - May 7th, 2026 6:14 am
Exelixis Seen Trading Steady on Modest Drug Growth, RBC Says - May 6th, 2026 11:41 am
EXEL Q1 Earnings Top Estimates, Colorectal Cancer Drug in Focus - May 6th, 2026 9:59 am